Fungal vaccines and vaccination: Problems and perspectives

Immunology of Fungal Infections

Volumn , Issue , 2007, Pages 465-485

  Cassone, Antonio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 43149113848     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/1-4020-5492-0_21     Document Type: Chapter

References (60)

1. Beninati, C., Oggioni M. R., Boccanera, M., Spinosa, M. R., Maggi, T., Conti, S., Magliani, W., De Bernardis, F., Teti, G., Cassone, A., Pozzi, G. and Polonelli, L. (2000) Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat. Biotechnol. 18, 1060-1064.
2. Bohn, J. A., Be Miller, J. N. (1995) Carbohydr. Polym. 28, 3-14.
3. Bozza, S., Montagnoli, C., Gaziano, R., Rossi, G., Nkwanyuo, G., Belloccio, S. and Romani, L. (2004) Dendritic cel-based vaccination against opportunistic fungi. Vaccine 22, 857-864.
4. Brian Mochon, A., Cutler, E. (2005) Is a vaccine needed against Candida albicans? Med. Mycol. 43, 97-115.
5. Bromuro, C., Torosantucci, A., Chiani, P., Conti, S., Polonelli, L. and Cassone, A. (2002) Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70, 5462-5470.
6. Brown, G. D. and Gordon, S. (2003) Fungal beta-glucans and mammalian immunity. Immunity 19, 311-315.
7. Casadevall, A. and Pirofski, L. A. (2006) Polysaccharide-containing conjugate vaccines for fungal diseases. Trends Mol. Med. 12, 6-9.
8. Casadevall, A., Feldmesser, M. and Pirofski, L. A. (2002) Induced humoral immunità and vaccination against major human fungal pathogens. Curr. Opin. Microbiol. 5, 386-391.
9. Casadevall, A., Dadachova, E. and Pirofski, L. A. (2004) Passive antibody therapy for fungal infections. Nat. Rev. Microbiol. 2, 695-703.
10. Cassone, A. (1986) Cell wall of pathogenic yeasts and implications for antimycotic therapy. Drugs Exp. Clin. Res. 12, 635-643.
11. Cassone, A., Torosantucci, A. (1991) Candida albicans, Springer-Verlag, Berlin Heidelberg.
12. Cassone, A., Conti, S., De Bernardis, F. and Polonelli, L. (1997) Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol. Today 18, 164-169.
13. Cassone, A. and Cauda, R. (2002) Response: HIV proteinase inhibitors: do they really work against Candida in a clinical setting? Trends Microbiol. 10, 177-178.
14. Chaffin, W. L. et al. 1998 Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol. Mol. Biol. Rev. 62, 130-80.
15. Chattaway, F. W., Holmes, M. R. and Barlow, A. J. (1968) Cell wall composition of the mycelial and blastospore forms of Candida albicans. J. Gen. Microbiol. 51, 367-376.
16. Cox, R. A. and Magee, D. M. (2004) Coccidioidomycosis: host response and vaccine development. Clin. Microbiol. Rev. 17, 804-839.
17. De Bernardis, F., Boccanera, M., Adriani, D., Girolamo, A. and Casone, A. (2002) Intravaginal and intranasal immunization are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect. Immun. 70, 2725-2729.
18. De Bernardis, F. et al. (2006) Humain domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidians. J. Infect. Dis., in press.
19. Deepe, G. S. Jr. (1997) Prospects for the developmentoffungal vaccines. Clin. Microbiol. Rev. 10, 585-596.
20. Deepe, G. S. Jr. (2004) Preventative and therapeutic vaccines for fungal infections: from concept to implementation. Expert. Rev. Vaccines. 3, 701-709.
21. Deepe, G. S. Jr., Wuthrich, M. and Klein, B. S. (2005) Progress in vaccination for histoplasmosis and blastomycosis: coping with cellular immunity. Med. Mycol. 43, 381-389.
22. Denning, D. W. (2003) Echinocandin antifungal drugs. Lancet 362, 1142-1151.
23. Feldmesser, M. (2005) Prospects of vaccines for invasive aspergillosis. Med. Mycol. 43, 571-587.
24. Gartner, B. N., Simmons, R. M. and Underhill, D. M. (2005) Dectin-1 mediates macrophage recognition of Candida albicans yeasts but not filaments. EMBO J. 24, 1377-1286.
25. Georgopapadakou, N. H. and Tkacz, J. S. (1995) The fungal cell wall as a drug target. Trends Microbiol. 3, 98-104.
26. Gow, N. A. R., Brown, A. J. P. and Odds, F. C. (2002) Fungal morphogenesis and host invasion. Curr. Opin. Microbiol. 5, 366-371.
27. Ibrahim, A. S., Spellberg, B. J., Avenissian, V., Fu, Y., Filler, S. G., Edwards, J. E. Jr. (2005) Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun. 73, 999-1005.
28. Klis, F. M., De Groot, P. and Hellingwerf, K. (2001) Molecular organization of the cell wall of Candida albicans. Med. Mycol. 39, 1-8.
29. Kumamoto, C. A. and Vinces, M. D. (2005) Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence. Cell Microbiol. 7, 1546-54.
30. Latgè, J. P. and Calderone, R. (2002) Host-microbe interactions: fungi invasive human fungal opportunistic infections. Curr. Opin. Microbiol. 5, 355-358.
31. Magliani, W., Conti, S., Salati, A., Arseni, S., Ravanetti, L., Frazzi, R. and Polonelli, L. (2004) Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr. Med. Chem. 11, 1793-1800.
32. Maitta, R. W., Datta, K., Lees, A., Belouski, S. S. and Pirofski, L. A. (2004) Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect. Immun. 72, 196-208.
33. Martinez, L. R. and Casadevall, A. (2005) Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect. Immun. 73, 6350-6362.
34. Masuoka, J. (2004) Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges. Clin. Microbiol. Rev. 17, 281-310.
35. Matthews, R. C. and Burnie, J. P. (2004) Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 22, 865-871.
36. Matthews, R. C., Rigg, G., Hodgetts, S., Carter, T., Chapman, C., Gregory, C., Illidge, C. and Burnie, J. (2003) Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47, 2208-2216.
37. Montagnoli, C., Bozza, S., Bacci, A., Gaziano, R., Mosci, P., Morschhauser, J., Pitzurra, L., Kopf, M., Cutler, J. and Romani, L. (2003) A role for antibodies in the generation of memory antifungal immunity. Eur. J. Immunol. 33, 1193-1204.
38. Oscarson, S., Alpe, M., Svahnberg, P., Nakouzi, A. and Casadevall, A. (2005) Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures. Vaccine 23, 3961-3972.
39. Pietrella, D., Corbucci, C., Perito, S., Bistoni, G. and Vecchiarelli, A. (2005) Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation. Infect. Immun. 73, 820-827.
40. Polak, A. (2003) Antifungal therapy-state of the art at the beginning of the 21st century. Prog. Drug. Res. (Spec. No.), 59-190.
41. Romagnoli, G., Nisini, R., Chiani, P., Mariotti, S., Teloni, R., Cassone, A. and Torosantucci, A. (2004) The interaction of human dendritic cells with yeast and germ-tube forms of Candida albicans leads to efficient fungal processing, dendritic cell maturation and acquisition of a Th1 response-promoting function. J. Leukoc. Biol. 75, 117-126.
42. Sanglard, D. (2002) Resistance of human fungal pathogens to antifungal drugs. Curr. Opin. Microbiol. 5, 379-385.
43. Santoni, G., Boccanera, M., Adriani, D., Lucciarini, R., Amantini, C, Morrone, S., Cassone, A. and De Bernardis, F. (2002) Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4 (+) T cells and possible participation of other local lymphocyte effectors. Infect. Immun. 70, 4791-4797.
44. Schaller, M., Bein, M., Korting, H. C., Baur, S., Hamm, G., Monod, M., Beinhauer, S. and Hube, B. (2003) The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect. Immun. 71, 3227-3234.
45. Schaller, M., Borelli, C, Korting, H. C. and Hube, B. (2005) Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 48, 365-377.
46. Sheppard, D. C. and Edwards, J. E. Jr. (2004) Development of a vaccine for invasive aspergillosis. Clin. Infect. Dis. 38, 1137-1138.
47. Sims, C. R., Ostrosky-Zeichner, L. and Rex, J. H. (2005) Invasive candidiasis in immunocompromised hospitalized patients. Arch. Med. Res. 36, 660-671.
48. Smulian, A. G., Sullivan, D. W. and Theus, S. A. (2000) Immunization with recombinant Pneumocystis carinii p55 antigen provides partial protection against infection: characterization of epitope recognition associated with immunization. Microbes. Infect. 2, 127-136.
49. Stevens, D. A. (2004) Vaccinate against aspergillosis! A call to arms of the immune system. Clin. Infect. Immun. 38, 1131-1136.
50. Stone, B. A. and Clark, A. E. (1992) Chemistry and biology of (1-3)-β-glucans. La Trobe University Press, Victoria, Australia.
51. Taborda, C. P., Nakaie, C. R., Cilli, E. M., Rodrigues, E. G., Silva, L. S., Franco, M. F. and Travassos, L. R. (2004) Synthesis and immunological activity of a branched peptide carrying the T-cell epitope of gp43, the major exocellular antigen of Paracoccidioides brasiliensis. Scand. J. Immunol. 59, 58-65.
52. Tarcha, E. J., Basrur, V., Hung, C. Y., Gardner, M. J. and Cole, G. T. (2006) A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice. Infect. Immun. 74, 516-527.
53. Torosantucci, A., Bromuro, C, Chiani, P., De Bernardis, F., Berti, F., Galli, C, Norelli, F., Bellucci, C, Polonelli, L., Costantino, P., Rappuoli, R. and Cassone, A. (2005) A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597-606.
54. Torres, M., May, R., Scharff, M. D. and Casadevall, A. (2005) Variable-region-identical antibodies differing in isotype demonstrate differences infine specificity and idiotype. J. Immuol. 174, 2132-2142.
55. Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R. and Lanzavecchia, A. (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10(8), 871-875
56. Van Der Graaf, C. A., Netea, M. G., Verschueren, I., Van Der Meer, J. W. and Kullberg, B. J. (2005) Differential cytokine production and Toll-like receptor signaling pathways by Candida albicans blastoconidia and hyphae. Infect. Immun. 73, 7458-7464.
57. Vilanova, M., Teixeira, L., Caramalho, I., Torrado, E., Marques, A., Madureira, P., Ribeiro, A., Ferreira, P., Gama, M. and Demengeot, J. (2004) Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunology 111, 334-342.
58. Wuthrich, M., Warner, T. and Klein, B. S. (2005) CD28 is required for optimal induction, but not maintenance, of vaccine-induced immunity to Blastomyces dermatitidis. Infect. Immun. 73, 7436-7441.
59. Zhang, M. X., Bohlman, M. C., Itatani, C, Burton, D. R., Parren, P. W., St Jeor S. C. and Kozel T. R. (2006) Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect. Immun. 74, 362-369.
60. Zheng, M., Ramsay, A. J., Robichaux, M. B., Norris, K. A., Kliment, C, Crowe, C, Rapaka, R. R., Steele, C, McAllister, F., Shellito, J. E., Marrero, L., Schwarzenberger, P., Zhong, Q. and Kolls, J. K. (2005) CD4 T cell-independent DNA vaccination against opportunistic infections. J. Clin. Invest. 115, 3536-3544.